Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and efficacy of combretastatin combined
with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).